financetom
Business
financetom
/
Business
/
Parsons Corp Q3 revenue misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Parsons Corp Q3 revenue misses estimates
Nov 5, 2025 3:57 AM

Overview

* Parsons Q3 2025 revenue declined 10% yr/yr, missing analyst expectations

* Adjusted EPS for Q3 2025 beats analyst expectations

* Adjusted EBITDA for Q3 2025 beats analyst expectations

* Company's backlog increased to $8.8 bln, highest funded level since IPO

Outlook

* Parsons modifies fiscal year 2025 revenue outlook to $6.4 bln - $6.5 bln

* Company reiterates adjusted EBITDA guidance at $600 mln - $630 mln

* Parsons maintains cash flow guidance at $380 mln - $460 mln

Result Drivers

* CONTRACT IMPACT - Revenue decline attributed to decreased revenue from a confidential contract, but excluding this, revenue grew 14%

* CRITICAL INFRASTRUCTURE GROWTH - Critical Infrastructure segment saw 18% revenue increase driven by organic growth and acquisitions

* ADJUSTED EBITDA MARGIN - Improved program performance and acquisitions led to a 60 basis point increase in adjusted EBITDA margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $1.60 $1.66

Revenue bln bln (10

Analysts

)

Q3 Beat $0.86 $0.75

Adjusted (10

EPS Analysts

)

Q3 Net $64 mln

Income

Q3 Beat $158 mln $153.24

Adjusted mln (8

EBITDA Analysts

)

Q3 $108 mln

Operatin

g income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the aerospace & defense peer group is "buy"

* Wall Street's median 12-month price target for Parsons Corp ( PSN ) is $90.26, about 11.8% above its November 4 closing price of $79.56

* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cummins Powers Through Truck Slump On Data Center Demand
Cummins Powers Through Truck Slump On Data Center Demand
Nov 6, 2025
Cummins Inc ( CMI ). shares rose after the company reported third-quarter 2025 results that exceeded Wall Street expectations, demonstrating resilience amid soft truck demand and continued strength in data center power markets. Revenue came in at $8.32 billion, above the $7.97 billion consensus, but down 2% year over year. Meanwhile, adjusted EPS of $5.59 also beat expectations of $4.81. GAAP...
ATEX Resources Raises $110 Million in a Bought-Deal Private Placement of Share Units
ATEX Resources Raises $110 Million in a Bought-Deal Private Placement of Share Units
Nov 6, 2025
12:06 PM EST, 11/06/2025 (MT Newswires) -- ATEX Resources ( ATXRF ) on Thursday said it closed an upsized bought-deal private placement of share units that raised $110 million, including the full exercise of the underwriters' option. The company said it sold underwriters 42.3-million units priced at $2.60 apiece and made up of a share and a four-year warrant to...
Becton sees 2026 profit slightly above estimates amid ongoing market challenges
Becton sees 2026 profit slightly above estimates amid ongoing market challenges
Nov 6, 2025
Nov 6 (Reuters) - Medical device maker Becton Dickinson ( BDX ) on Thursday topped Wall Street estimates for fourth-quarter adjusted profit and forecast 2026 earnings slightly above expectations. However, in a conference call, the company's executives warned of persistent headwinds in China, softer vaccine demand and a ramp-down in its Alaris infusion pumps after record installations. Becton, which makes...
Factbox-What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Factbox-What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Nov 6, 2025
(Reuters) -Pfizer ( PFE ) and Novo Nordisk are locked in a bidding war for biotech firm Metsera ( MTSR ) as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market. WHAT IS METSERA? Metsera ( MTSR ) is a New York-based clinical-stage biotech firm focused on developing treatments for obesity and metabolic diseases. Founded...
Copyright 2023-2026 - www.financetom.com All Rights Reserved